R01 / Beijing Anjianxi Bio-Medical - LARVOL DELTA

Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Beijing Anjianxi Bio-Medical Technology Co., Ltd.

Monotherapy • New P1 trial • Esophageal Cancer • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A phase I dose-escalation study of a first-in-class HIF1 and HIF2 dual inhibitor R01 in patients with advanced tumors. (ASCO 2025) - P1 | "R01 has shown an extremely excellent safety profile, favorable pharmacokinetics, and very encouraging activity across a broad range of tumor types. Recruitment into the phase-2 part of the study is ongoing. Clinical trial information: ChiCTR2500095101."

Clinical • IO biomarker • Metastases • P1 data • Anemia • Colorectal Cancer • Fatigue • Head and Neck Cancer • Leukopenia • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia • HIF1A • KRAS • PD-L1 • TP53